

**FUJIFILM**

**Diosynth**  
biotechnologies

2020/21

# FUJIFILM Diosynth Biotechnologies Denmark ApS, Annual Report

Approved at the Company's annual general meeting on 30 August 2021

Chairman:

*M. Meeson*



Signer Name: Martin Meeson

Signing Reason: I approve this document

Signing Time: 30-Aug-2021 | 06:32:47 EDT






We deliver  
life-changing  
medicines.

## Contents

Statement by Board of Directors and Executive Management .....	5
Independent auditor's report .....	6
Management's review .....	11
Financial statements 1 April 2020 - 31 March 2021 .....	19
Income statement .....	19
Balance sheet .....	20
Statement of changes in equity .....	21
Notes to the financial statements.....	22







# Statement by the Board of Directors and the Executive Management

Today, the Board of Directors and the Executive Management have discussed and approved the annual report of FUJIFILM Diosynth Biotechnologies Denmark ApS for the financial year 1 April 2020 - 31 March 2021.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the company at 31 March 2021 and of the results of the company's operations for the financial year 1 April 2020 - 31 March 2021.

Further, in our opinion, the Management's review gives a fair review of the development in the company's operations and financial matters and the results of the company's operations and financial position.

We recommend that the annual report be approved at the annual general meeting.


Copenhagen, 30 August 2021

Executive Management:

DocuSigned by:  
  
 Signer Name: lars petersen  
 Signing Reason: I approve this document  
 Signing Time: 30-Aug-2021 | 08:14:36 EDT  
 7CD7D0252D534EF9BB5EDBD484AE25BF

Board of Directors:

DocuSigned by:  
  
 Signer Name: Martin Meeson  
 Signing Reason: I approve this document  
 Signing Time: 30-Aug-2021 | 06:33:10 EDT  
 15D84FA4C7C4B458923D3E6E5ED0629

DocuSigned by:  
  
 Signer Name: lars petersen  
 Signing Reason: I approve this document  
 Signing Time: 30-Aug-2021 | 08:15:04 EDT  
 7CD7D0252D534EF9BB5EDBD484AE25BF

DocuSigned by:  
  
 Signer Name: Toshihisa Iida  
 Signing Reason: この文書を承認する  
 Signing Time: 29-8-2021 | 12:03:09 EDT  
 F318A71B0C944C499E826DFD25F87837

DocuSigned by:  
  
 Signer Name: Takatoshi Ishikawa  
 Signing Reason: この文書を承認する  
 Signing Time: 29-8-2021 | 20:14:29 EDT  
 2352FC1A89664DEE80CE01F1E267FEAC

# Independent Auditor's Report

## To the shareholders of FUJIFILM Diosynth Biotechnologies Denmark ApS

### Opinion

We have audited the financial statements for the financial year 1 April 2020 - 31 March 2021 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 March 2021, and of the results of the Company's operations for the financial year 1 April 2020 - 31 March 2021 in accordance with the Danish Financial Statements Act.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue

as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

## Independent auditor's report

- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Copenhagen, 30 August 2021

KPMG

Statsautoriseret Revisionspartnerselskab

CVR no. 25 57 81 98



Niels Vendelbo

State Authorised Public Accountant

mne34532

## Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.





Martin Yde Schmidt

State Authorised Public Accountant

mne42821







# Company details

Name.....FUJIFILM Diosynth Biotechnologies Denmark ApS

Address, Postal code, City..... Biotek Allé 1, 3400 Hillerød

CVR no. ....26 06 07 02

Established..... 1 June 2001

Registered office ..... Hillerød

Financial year ..... 1 April 2020 - 31 March 2021

Website..... [www.fujifilmdiosynth.com](http://www.fujifilmdiosynth.com)

Telephone ..... +45 77 41 60 00

Board of Directors ..... Martin Edward Meeson, Chair  
Toshihisa Iida  
Takatoshi Ishikawa  
Lars Petersen

Executive Management ..... Lars Petersen, COO

Auditors ..... KPMG Statsautoriseret Revisionspartnerselskab  
Dampfærgevej 28, 2100 Copenhagen Ø








# Management review

## Financial highlights

DKK'000	2020/21 12 months	2019/20 15 months	2018 12 months	2017 12 months	2016 12 months
<b>Key figures</b>					
Revenue	2,727,431	2,039,469	1,417,166	1,417,224	1,275,316
Gross profit	494,437	65,121	214,188	241,078	228,378
Net financials	-85,247	10,972	4,453	28,922	-13,522
<b>Profit/loss for the year</b>	<b>103,550</b>	<b>-176,316</b>	<b>253,501</b>	<b>170,735</b>	<b>109,185</b>
<b>Total assets</b>					
Total assets	5,848,427	5,495,135	4,540,602	4,416,378	4,646,497
Investments in property, plant and equipment	473,378	103,646	132,947	163,053	193,078
<b>Equity</b>	<b>3,865,418</b>	<b>3,761,868</b>	<b>3,938,184</b>	<b>3,684,683</b>	<b>3,513,948</b>
<b>Financial ratios</b>					
Operating margin	8.0%	-11.6%	22.4%	11.9%	11.0%
Gross margin	18.1%	3.2%	15.1%	17.0%	17.9%
Return on assets	3.9%	-2.5%	3.2%	3.7%	3.1%
Equity ratio	66.1%	68.5%	86.7%	83.4%	75.6%
Return on equity	2.7%	-4.6%	6.7%	4.7%	3.2%
<b>Average number of employees</b>					
<b>Average number of employees</b>	<b>813</b>	<b>746</b>	<b>747</b>	<b>709</b>	<b>596</b>

For terms and definitions, please see the accounting policies.





Lars Petersen, COO,  
FUJIFILM Diosynth Biotechnologies Denmark



**The expansion will be transformative, significantly expanding our ability to support current and future partners, infusing sustainability efforts into future operations, and further strengthening our leadership in biologic drug substance manufacturing.**

## Message from Executive Management

We look at the financial year 2020/21 as a successful year for our company. It was the first full financial year for FUJIFILM Diosynth Biotechnologies Denmark under the ownership of FUJIFILM Corporation and as part of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization for biologics and advanced therapies. The company delivered DKK 2,727.4 million in revenue and DKK 132.8 million in profit before tax. The revenue was higher than expected driven by a higher demand for manufacturing activities.

The result before tax is despite the pandemic challenges within the range of last year's outlook. The revenue and gross profit exceeded expectations for the year, however the result was impacted by net financials due to a decrease in the USD exchange rate.

Our manufacturing services and expertise have brought new customers and new programs, which also solidified our position as a trusted partner for large-scale biologics manufacturing.

### **A different year**

The year was affected by the pandemic and one of the largest risks for our manufacturing operations was to secure raw materials for production. We navigated successfully through the pandemic in close collaboration with our colleagues and customers resulting in uninterrupted manufacturing operations.

During the pandemic the demand for manufacturing capacity increased and our long-term plan and outlook remain positive.

### **New investment**

On 9 June 2020 FUJIFILM Corporation announced that it will invest 100 billion yen (DKK 6.1 billion) into our company. This investment will double our current drug substance manufacturing capacity, expand our capabilities to include fill/finish, and enhance our current assembly, labeling and packaging services. The expansion will be transformative, significantly expanding our ability to support current and future partners, infusing sustainability efforts into future operations, and further strengthening our leadership in biologic drug substance manufacturing. We are excited to see the site grow and to welcome 300 new employees in the future.





# Our Business

## Purpose

FUJIFILM Diosynth Biotechnologies Denmark (FDBD) is a part of FUJIFILM Diosynth Biotechnologies (FDB), a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies. FDB offers complete solutions in pharmaceutical manufacturing – from pre-clinical investigations and process development to commercial cGMP production. The focus is to combine technical leadership in cell culture, microbial fermentation and gene therapies with world class cGMP manufacturing facilities to advance tomorrow's medicines.

Our purpose is along with the FDB group is to be the leading and most trusted global Contract Development and Manufacturing Organization partner in the biopharmaceutical industry.

## Financial model

FDBD is a financially independent company and a subsidiary of FUJIFILM Corporation.

## Change of ownership

On 1 August 2019, the company was acquired by FUJIFILM Corporation based in Tokyo from US-based Biogen Inc. The acquisition included transition of all employees working at the Hillerød site. The change of ownership also included a change of financial year resulting in a 2019/20 reporting year of 15 months. The financial year 2020/21 was therefore the first full financial year under the FUJIFILM ownership as a part of FUJIFILM Diosynth Biotechnologies.

The company is now a Contract Development and Manufacturing Organization ("CDMO") as part of the FDB group.





The main business areas all performed from the manufacturing site in Hillerød.



**Business area**

**Drug Substance Manufacturing**

Our large-scale drug substance manufacturing facility has a capacity of 120,000 liters to reliably manufacture biopharmaceuticals for late phase and commercial use.

**Business area**

**Assembly, Label and Pack**

Our facility for assembly, label and pack manufactures advanced delivery systems and ensures required labelling and secure packaging of the therapies for patients worldwide.

The site also houses quality control laboratories, warehouses, and a number of organizations, supporting manufacturing activities: process science, supply chain management, engineering and quality assurance

# Financial review

**A significant improvement in the activities in the business areas resulting in higher than expected revenue.**

## Revenue and profit

The company delivered a total revenue of DKK 2,727.4 million in financial year 2020/21 compared to DKK 2,039.5 million in the previous period. Financial year 2019/20 was considered to be a transition year due to the change of ownership and lower amount of manufacturing activities as well as a manufacturing maintenance slowdown and expenses related to the transition. In addition, it should be noted that the previous period covered a 15-month financial year due to the change in reporting period.

The growth in revenue was 34%, which exceeded expectations.

The revenue was negatively impacted throughout the year by USD exchange rates.

Profit before tax was DKK 132.8 million in the year compared to a loss of DKK 226.0 million in the previous year. The improvement can be attributed to the increased manufacturing activities in the drug substance area.

## Net profit

FDBD reported net profit of DKK 103.6 million in 2020/21 compared to a loss of DKK 176.3 million in 2019/20.

## Investments

FDBD invested a total of DKK 473.4 million in tangible fixed assets in 2020/21. The investments are covering the operational capital investment to support the continuous manufacturing as well the expansion of the facility in building for the future project. COVID-19 was considered to have an impact in the earlier part of the year, but the company managed to pick up during the second half of the year.

Total assets increased in 2020/21. At year-end the total assets was DKK 5,848.4 million compared to the DKK 5,495.1 million the year before.

## Equity

At the end of the financial year the equity shows DKK 3,865 million. The equity ratio decreased from 68.5% in 2019/20 to 66.1% in 2020/21.

## Events after the balance sheet date

Since the end of the financial period and until this date, there have been no events, which materially change the presentation of the annual report.

## Employees

We strive to be an attractive workplace, that can attract and retain the right employees with the right knowledge. This is essential to our current and future success.

At the end of 2020/21 the company had 881 full time employees, which was 133 employees more than the 748 employees the year before. This increase in employees is driven by increase in business activities and starting project related expansion activities on the site. All of the employees work from the company's site in Hillerød.

## Statutory CSR Report

### Corporate social responsibility

Our commitment is grounded in the FUJIFILM Code of Conduct, the FUJIFILM Healthcare Code of Conduct and other related policies and position statements. These principles and policies outline our focus on ethical business conduct, compliance, accountability and transparency and other topics as they relate to the business of the FUJIFILM group. In Denmark, these efforts are primarily focused around our core business activities of manufacturing, quality assurance and packing of biologics.

The FUJIFILM Code of Conduct provides guidance on making ethical decisions while conducting business of the company. The Code of Conduct helps employees apply core values to specific situations in the day-to-day activities. The Code of Conduct serves as the company baseline standard and as a guide to other written standards, such as policies, procedures, and functional guidance.

FUJIFILM Corporation has established a Sustainable Value Plan 2030 on Corporate Social Responsibility that ensures top management commitment and accountability and sets a framework for FDB and FDBD. The Sustainable Value Plan 2030 is based upon the UN Sustainable Development Goals and sets targets for the sustainability efforts in FUJIFILM.

Information on Fujifilm global strategies, commitments and efforts regarding social responsibility and sustainability is available at <https://holdings.fujifilm.com/en/sustainability>. FUJIFILM Corporation issues an annual Sustainability report, which also includes our company. The report is available at <https://holdings.fujifilm.com/en/sustainability/report/2020>.

FDBD is aware of the impact of the company has on society, people and environment. The company has evaluated both risks and opportunities based on the UN Sustainable Developments Goals. Based on the expectation that companies participate in building a sustainable society, the company has therefore based long-term and mid-term plans on improvements on the UN Sustainable Developments Goals.





**Environment**

Address Climate Change ■ ■  
 Promote Recycling of Resources ■

**UN SDG**  
 SDG 6, SDG 12, SEG 13

**Health**

Promote a Healthy Work Place ■

**UN SDG**  
 SDG 3

**Work Style**

Create Environments that Lead to a Motivated Workplace ■ ■  
 Develop Diverse Human Resources ■

**UN SDG**  
 SDG 5, SDG 8

**Supply Chain**

Strengthen CSR Foundations Across the Entire Supply Chain ■ ■

**UN SDG**  
 SDG 12

■ Opportunity ■ Risk

**Environmental, health and safety**

Our Environmental, Health and Safety (EHS) Policy Statement sets forth our commitment to provide and maintain a healthy and safe work environment and to minimize the impact of our business operations and products on the environment.

FDBD works to ensure more sustainable production. The company is subject to public regulations according to the Danish Environmental Protection Act, including regulations relating to use of energy, discharge of waste water from production equipment and disposal of materials used in the production unit, labelling & packaging or laboratory. FDBD has established and maintained effective procedures and systems to adhere to the principles of this Policy and track progress against the EHS strategy. The EHS Management Systems are certified on international recognized standards – ISO14001 Environmental Management, ISO50001 Energy Management and ISO45001 Health and Safety Management covering environment, climate change, social responsibility and employee related topics.

An integral part of the ISO Certifications is to set targets and goals and follow up annually in a Management Review. This process and the results of the process are audited annually by an independent external certifying agency. The Management Review also identifies risks and opportunities on Environment, Energy and Health & Safety ensuring that risks are addressed and actions taken to mitigate. This risks are estimated to be low.

Our employees are responsible for knowing and adhering to the company EHS Policy. All employees are expected to act responsibly and follow EHS policies and procedures in order to protect themselves, their co-workers, the community, the environment and the company. As necessary, all employees are required to attend safety classes specifically tailored to their lines of work. The company emphasizes a proactive safety culture involving employees in mitigation of identified risks at the work place as this will affect the lost time injury rate positively. The lost time injury rate for 2020 was 4.2 per million work hours.

The company continues the engagement in Hillerod Symbiose where the company collaborates with the local community and other industrial companies to identify and implement environmental improvements locally. In 2020 a project on waste water was completed within the Hillerod Symbiose framework on waste water treatment. This project has resulted in savings in use of chemicals for waste water treatment up to 400 tons per year. Reducing the environmental footprint also includes energy saving projects. In 2020 the company has carried out projects on energy savings. The project with the biggest impact on energy savings was the implementation of a more energy efficient water treatment unit.

EHS is included in several sections of the FUJIFILM Code of Conduct. All employees are trained in the FUJIFILM Code of Conduct and EHS as part of their introduction.

FUJIFILM Corporation has established

a Sustainable Value Plan 2030, which sets environmental goals to reduce the total environmental impact from FUJIFILM activities and contribute to the resolution of environmental issues. The plan sets goals to create a health society through impacting healthcare as well as support daily life with support various aspects of social infrastructure. For additional information FUJIFILM Sustainable Value Plan 2030 is available at <https://holdings.fujifilm.com/en/sustainability/report/2020>

**Anti-monetary laundering and Anti-corruption**

FDBD has as part of the FUJIFILM Code of Conduct and supporting policies, an Anti-Monetary Laundering policy and Anti-Corruption policy, which sets forth a commitment to preventing and detecting bribery and corruption of all types, and set the basic standards for interactions with all third parties, including commercial counterparts, healthcare professionals, government employees and government entities. All employees are trained in the FUJIFILM Code of Conduct.

FDBD has implemented internal procedures to prevent money laundering and corruption. These processes are audited on a regular basis and no violations have been identified. The company has identified the risk of violation of company policies as the main risk associated with bribery and corruption, but due to thorough implementation and monitoring, this risk is estimated to be low. The company is committed to continue its efforts against bribery and corruption in the future.



## Human rights

The company respects fundamental human rights and believes that every individual deserves to be treated fairly and with dignity. The company is committed to supporting internationally recognized fundamental human rights activities and initiatives. FUJIFILM embrace the United Nations' Guiding Principles on Business and Human Rights (UNGPs) as a framework for implementation of respecting human rights. As a responsible organization, the company respects the human rights of all people with whom we interact, including our patients, customers, employees and third parties who work as our external business partners.

Fair working conditions and Human Rights are included as a section of the FUJIFILM Code of Conduct as well as in our terms and conditions for contracts with suppliers. All employees are trained in the FUJIFILM Code of Conduct.

The processes including Human Rights are audited on a regular basis and no violations were identified. The company has identified the risk of violation of company policies as the main risk associated with human rights, but due to thorough implementation and monitoring, this risk is estimated to be low. The company is committed to continue its human rights efforts in the future.

For additional information, FUJIFILM human rights statement is available at <https://holdings.fujifilm.com/en/sustainability/vision/policy/statement>

## Community

FDBD recognizes our responsibility to conduct business in a way that protects and improves our environment and the local community. As part of manufacturing products for our clients, FDBD continuously works to minimize the environmental impact in all our processes. The company strives to minimize our use of natural resources, reduce waste, and mitigate our impact on climate change. FDBD proactively assesses environmental risks and opportunities to continuously improve our performance.

The company has not identified any operations with significant potential

or actual negative impact on local communities. FDBD continuously makes assessments to ensure that the impact of our operations on our local communities remains minimal. These include environmental assessments and traffic flow strategies. FDBD aims to have a positive impact in the local community through our community programs and participation in Hillerød Symbiose – a partnership of local industries, public companies and authorities. However some of the community initiatives have proved to be a challenge throughout the pandemic.

## Account of the gender composition of Management

### Diversity

In FDBD, employees and board members are always selected based on qualifications and skills, striving for an equal representation of genders at all levels. The company wants to be an attractive employer and a workplace with focus on diversity including gender equality.

At the end of 2020/21 the board consists of 4 male board members. The board is currently consisting of two members appointed by FUJIFILM Corporation, the CEO of the FDB Group and the COO of the FDBD. We recognize that the diversity target for the board is hard to achieve, but we aim to increase female representation in the board by 2025, targeting 25%.

The upper management levels (associate director+) currently consist of 42% females and 58% males and the gender composition is therefore considered to be satisfactory. The company will continue focus on an equal representation of gender going forward.

The company aims to have a diverse culture. At the end of 2020/21 the company had 881 full-time employees with more than 40 different nationalities.

## Outlook

### The outlook for 2021/22

The expectation for the 2021/22 is lower compared to 2020/21 due to the financial impact of the ongoing expansion and investments for building the structure and readiness for the future. This expectation

is despite the increased demand and interest from new clients.

The stable demand and the ability to keep uninterrupted manufacturing have proven to be a necessary component in the performance of the company in unstable times like during the pandemic. We will continuously focus on long range planning, but keeping flexibility for our clients going forward as well.

The large-scale drug substance manufacturing is expected to continue at approximately the same level of manufacturing activity in 2021/22 with some differences in the production mix due to new clients and programs.

The assembly, label and packaging and quality control will continue the activities at approximately the same level as in 2020/21, although this will be subject to demand-based fluctuations inherent in the pharmaceutical industry.

The revenue is expected to be close to 2020/21 revenue and profit before tax for 2021/22 is expected to be between DKK 30-70 million. The expected decrease in profit is driven by expanding functions to support the new growth and impacted by an expected weak USD exchange rate.

## Building for the future

On the 9 June 2020 FUJIFILM Corporation announced that it will make an investment of approximately DKK 6,1 billion into our company. The investment will double our current drug substance manufacturing capacity, expand its capabilities to include fill/finish, and enhance its current assembly, labelling and packaging services.

The investment in FDBD will expand production lines for bulk drug substance with the addition of six bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023, making our facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry. The development will also include the addition of a fill/finish production line and a new packaging line equipped to assemble multiple types of auto-injectors as well as perform automatic labelling to meet a broad range of customer needs.



## Business risks

### Industry risks

As part of a global Contract Development and Manufacturing Organization in the Biopharmaceutical industry, the company is subject to the health authorities' regulated product requirements relating to drugs for patient treatment purposes. Quality of the services performed by FDBD is the license to operate.

In the Biopharmaceutical industry there are always general risks related to a large degree of uncertainty in relation to research and development of new products and the strong public regulations governing the industry. FDBD as a CDMO is also impacted by these risks through our clients.

### Operations and business continuity

FDBD is in the drug substance manufacturing highly dependent on being able to ensure uninterrupted manufacturing. A failure in the continuous manufacturing could result in loss of product in manufacturing. Therefore a business continuity approach is of great importance in the operations. FDBD has a business continuity plan in place to support the operations and mitigate potential risks.

### Quality of the product

FDBD is highly dependent on the quality of the services delivered to the clients. This is an essential part of building customer trust. Failure in delivering high quality services could result in a negative reputational impact to FDBD and FDB. This risk is managed by quality management systems, GMP standard operating procedures in addition to highly skilled employees.

### Knowledgeable resources

FDBD is operating in the area of manufacturing of biopharmaceutical products with a high degree of specialised knowledge. FDBD strives to be an attractive workplace, who can attract and retain the right employees with the right knowledge. This is essential to our current and future success.

### IT infrastructure and security

The IT infrastructure and security is an important part of ensuring continuous manufacturing operations. FDBD has IT security policies and procedures in place.

## Financial risks

### Credit risks

The clients of FDBD are typically large pharmaceutical companies. The distribution is not widely spread as the company mainly operates with a fewer number of clients. The business model for the services provided by FDBD includes some level of prepayment. The standard procedures for managing credit risks and managed clients credit agreements are in place.

### Financial risks

FDBD has cash available to cover manufacturing operations and to partly finance the expansion projects. However a significant part of the expansion projects will have to be financed through loan agreements. The company risk management is coordinated with FUJIFILM Corporation Europe Treasury. FDBD is participating in a FUJIFILM cash pool solution and has internal loan agreements with FUJIFILM Europe.

### Interest risk

FDBD is not significantly exposed to interest risk. The company does have loans from financing in the period of change of ownership. These loan agreements are internal with FUJIFILM Corporation Europe. The risk is considered to be moderate.

### Foreign exchange risks

FDBD has clients worldwide and the significant part of the financial activities are performed in USD. All manufacturing and supporting activities is performed in Denmark in local currency. The conclusion is that FDBD have significant currency risks and is quite heavily exposed to fluctuations in the USD exchange rate.

The company is continuously evaluating potential risk mitigation for future manufacturing operations and financial periods, but does not make use of any instruments such as hedging of foreign exchange exposure currently. The company therefore have no risk from usage and management of financial instruments.



# Financial statements

## 1 April 2020 - 31 March 2021

### Income statement

Note DKK'000	2020/21 12 months	2019/20 15 months
2 Revenue	2,727,431	2,039,469
3.4 Production costs	-2,232,994	-1,974,348
<b>Gross profit</b>	<b>494,437</b>	<b>65,121</b>
3.4 Administrative expenses	-271,942	-191,182
<b>Operating profit/loss</b>	<b>222,495</b>	<b>-126,061</b>
5 Other operating expenses	-4,497	-110,943
<b>Profit/loss before net financials</b>	<b>217,998</b>	<b>237,004</b>
6 Financial income	27,503	28,214
7 Financial expenses	-112,750	-17,242
<b>Profit/loss before tax</b>	<b>132,751</b>	<b>-226,032</b>
8 Tax for the year	-29,201	49,716
<b>Profit/loss for the year</b>	<b>103,550</b>	<b>-176,316</b>

# Financial statements

## 1 April 2020 - 31 March 2021

### Balance sheet

Note DKK'000

	2020/21	2019/20
<b>ASSETS</b>		
<b>Fixed assets</b>		
<b>9 Intangible assets</b>		
Acquired intangible assets	140,053	92,214
Knowhow and Customer Rights	320,605	458,008
Intangible assets in progress	53,355	90,435
	514,013	640,657
<b>10 Property, plant and equipment</b>		
Land and buildings	1,735,393	1,860,758
Fixtures and fittings, other plant and equipment	1,384,076	1,541,649
Leasehold improvements	0	0
Property, plant and equipment in progress	495,854	56,620
	3,615,323	3,459,027
<b>Total fixed assets</b>	4,129,336	4,099,684
<b>Non-fixed assets</b>		
<b>Inventories</b>		
Raw materials and consumables	473,196	409,082
	505,274	409,082
<b>Receivables</b>		
Trade receivables	339,226	421,301
Work in progress	544,554	468,745
Receivables from group enterprises	682	0
Other receivables	8,463	31,791
<b>11 Prepayments</b>	21,059	15,076
	913,984	936,913
<b>Cash</b>	331,911	49,456
<b>Total non-fixed assets</b>	1,719,091	1,395,451
<b>TOTAL ASSETS</b>	5,848,427	5,495,135



# Financial statements


## 1 April 2020 - 31 March 2021

Note DKK'000	2020/21	2019/20
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
12 Share capital	390	390
Retained earnings	3,865,028	3,761,478
<b>Total equity</b>	<b>3,865,418</b>	<b>3,761,868</b>
<b>Provisions</b>		
13 Deferred tax	202,946	181,871
<b>Total provisions</b>	<b>202,946</b>	<b>181,871</b>
<b>Liabilities other than provisions</b>		
<b>Non-current liabilities other than provisions</b>		
Prepayments received from customers	136,704	0
<b>Current liabilities other than provisions</b>		
Prepayments received from customers	291,681	0
Trade payables	409,387	267,925
Payables to group enterprises	810,245	1,143,954
Corporation tax payable	8,583	457
Other payables	123,463	139,060
	<b>1,643,359</b>	<b>1,551,396</b>
	<b>1,780,063</b>	<b>1,551,396</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,848,427</b>	<b>5,495,135</b>

- 1 Accounting policies  
 14 Contractual obligations and contingencies, etc.  
 15 Collateral  
 16 Related parties  
 17 Fee to the auditors appointed by the Company in general meeting  
 18 Appropriation of profit/loss

### Statement of changes in equity

Note DKK'000	Share capital	Retained earnings	Total
<b>Equity at 1 January 2019</b>	390	3,937,794	3,938,184
18 Transfer, see "Appropriation of profit/loss"	0	-176,316	-176,316
<b>Equity at 1 April 2020</b>	390	3,761,478	3,761,868
18 Transfer, see "Appropriation of profit/loss"	0	103,550	103,550
<b>Equity at 31 March 2021</b>	<b>390</b>	<b>3,865,028</b>	<b>3,865,418</b>



# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

#### 1 Accounting policies

The annual report of FUJIFILM Diosynth Biotechnologies Denmark ApS for 2020/21 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.

Effective from the financial year 2020, the Company has implemented amending act no. 1716 of 27 December 2018 to the Danish Financial Statements Act. The implementation of the amending act has not affected the Company's accounting policies on recognition and measurement of assets and liabilities but has solely entailed a requirement for further disclosures. The accounting policies used in the preparation of the financial statements are consistent with those of last year.

#### Omission of a cash flow statement

With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are reflected in the consolidated cash flow statement for the higher-ranking parent company.

#### Basis of recognition and measurement

The annual report has been prepared under the historical cost method.

Revenues are recognised in the income statement as earned, which includes recognition of value adjustments of financial assets and liabilities measured at fair value or amortised cost. Furthermore, all costs incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognized in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company and the value of the asset can be measured reliably.

Liabilities are recognized in the balance sheet when it is probable that future economic benefits will flow out of the Company and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

#### Reporting currency

The financial statements are presented in Danish kroner (DKK'000).

#### Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

# Financial statements

1 April 2020 - 31 March 2021

## Notes to the financial statements

### 1 Accounting policies (continued)

#### Income statement

##### Revenue

The Company has chosen IFRS 15 (Revenue from Contracts with Customers) as the basis for interpretation for revenue recognition.

Revenue includes service fees for biologic bulk production and assembly, labelling and products to be distributed to external clients. Service fees are recognised exclusive of VAT.

Revenue for biologic bulk production is based on the input method cost incurred and is recognised over time as the company has a right to payment for services performed and materials used in production.

##### Production costs

Production costs comprise costs incurred in generating the revenue for the year. Such costs include direct and indirect costs of raw materials, consumables and production staff, rent and leases, as well as depreciation on production plant.

Production costs also comprise research and development costs that do not qualify for capitalisation and amortisation of capitalised development costs.

##### Administrative expenses

Administrative expenses include expenses incurred in the year for company management and administration, including expenses relating to administrative staff, Management, office premises and expenses as well as amortisation/depreciation of assets used for administrative purposes.

##### Other operating expenses

Other operating expenses comprise items of a secondary nature relative to the Company's core activities, including gains or losses on the sale of fixed assets.

#### Amortisation/depreciation

The item comprises amortisation/depreciation of intangible assets and property, plant and equipment.

The basis of amortisation, which is calculated as cost less any residual value, is amortised on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Knowhow and Customer Rights	4 years
Software	0-5 years

The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further amortisation charges are recognised. In case of changes in the residual value, the effect on the amortisation charges is recognised prospectively as a change in accounting estimates.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Land and buildings	15-40 years
Fixtures and fittings, other plant and equipment	6-20 years
Leasehold improvements	3-5 years
Computer hardware	3-5 years

# Financial statements

1 April 2020 - 31 March 2021

## Notes to the financial statements

### 1 Accounting policies (continued)

The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further amortisation charges are recognised. In case of changes in the residual value, the effect on the amortisation charges is recognised prospectively as a change in accounting estimates.

### Financial income and expenses

Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

### Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

## Balance sheet

### Intangible assets

Knowhow and Customer rights are amortised over the expected economic life of the asset, measured by reference to Management's experience in the individual business segments. Knowhow and Customer rights are amortised on a straight-line basis over the amortisation period, which is 4 years. The amortisation period is based on the expected length of the inherent contracts.

Other intangible assets include software.

Other intangible assets are measured at cost less accumulated amortisation and impairment losses.

Gains and losses on the sale of intangible assets are recognised in the income statement under "Other operating income" or "Other operating expenses", respectively. Gains and losses are calculated as the difference between the selling price less selling expenses and the carrying amount at the time of sale.

### Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Gains or losses are calculated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses from the disposal of property, plant and equipment are recognised in the income statement as other operating income or other operating expenses.



# Financial statements

1 April 2020 - 31 March 2021

## Notes to the financial statements

### 1 Accounting policies (continued) Leases

The Company has chosen IAS 17 as interpretation for classification and recognition of leases.

Leases that do not transfer substantially all the risks and rewards incident to the ownership to the Company are classified as operating leases. Payments relating to operating leases and any other rent agreements are recognised in the income statement over the term of the lease. The Company's aggregate liabilities relating to operating leases and other rent agreements are disclosed under "Contingent liabilities".

### Impairment of fixed assets

The carrying amount of intangible assets, property, plant and equipment and investments in subsidiaries and associates is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists. Impairment losses on goodwill are not reversed.

### Inventories

Inventories are measured at cost in accordance with the FIFO method. Where the net realisable value is lower than cost, inventories are written down to this lower value. The net realisable value of inventories is calculated as the sales amount less costs of completion and expenses required to effect the sale and is determined taking into account marketability, obsolescence and development in the expected selling price.

The cost of raw materials and consumables comprises the cost of acquisition plus delivery costs.

The cost of finished goods and work in progress includes the cost of raw materials, consumables, direct labour and indirect production overheads.

Indirect production overheads include the indirect cost of material and labour as well as maintenance and depreciation of production machinery, buildings and equipment and expenses relating to plant administration and management.

### Receivables

Receivables are measured at amortised cost.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

#### 1 Accounting policies (continued)

##### Work in progress

Work in progress is measured at sales value of the work carried out. The sales value is measured on the basis of the level of completion at the balance sheet date and the expected income from the work in progress.

If the sales value cannot be calculated reliably, the sales value is measured at expenses incurred or net realisation value, if lower.

##### Prepayments

Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.

##### Cash

Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.

##### Income taxes and deferred tax

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

##### Liabilities

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

##### Prepayments received from customers

Prepayments received from customers primarily consist of amounts received from customers as reservation fees for future production. The prepayments will be deducted in future production fees.

##### Segment information

The allocation of revenue to activities and geographical markets is disclosed where these activities and markets differ significantly in the organisation of sales of goods and services.

# Financial statements

## 1 April 2020 - 31 March 2021

### **Notes to the financial statements**

1 Accounting policies (continued)

### **Financial ratios**

*The financial ratios stated under "Financial highlights" have been calculated as follows:*

<b>Operating profit/loss</b>	Profit/loss before financial items adjusted for other operating income and other operating expenses
<b>Operating margin</b>	$\frac{\text{Operating profit (EBIT)} \times 100}{\text{Revenue}}$
<b>Gross margin</b>	$\frac{\text{Gross profit/loss} \times 100}{\text{Revenue}}$
<b>Return on assets</b>	$\frac{\text{Profit/loss from operating activities} \times 100}{\text{Average assets}}$
<b>Equity ratio</b>	$\frac{\text{Equity, year-end} \times 100}{\text{Total equity and liabilities, year-end}}$
<b>Return on equity</b>	$\frac{\text{Profit/loss after tax} \times 100}{\text{Average equity}}$

# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

DKK'000

	2020/21 12 months	2019/20 15 months
<b>2 Segment information</b>		
<b>Breakdown of revenue by geographical segment:</b>		
USA	963,084	882,343
Europe	1,055,035	668,835
Asia	709,312	488,291
	2,727,431	2,039,469

### 3 Staff costs

Wages/salaries	621,534	701,466
Pensions	51,529	58,682
Other social security costs	8,923	11,481
	681,986	771,629

Staff costs are recognised as follows in the financial statements:

Production	599,641	690,968
Administration	82,345	80,661
	681,986	771,629
Average number of full-time employees	813	746

By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to Management is not disclosed.

### 4 Amortisation/depreciation of intangible assets and property, plant and equipment

Amortisation of intangible assets	175,146	119,432
Depreciation of property, plant and equipment	312,584	387,766
	487,730	507,198

Amortisation/depreciation of intangible assets and property, plant and equipment are recognised in the income statement under the following items, Production costs with DKK 447,526 thousand and Administrative expenses with DKK 40,204 thousand.

### 5 Other operating expenses

Other operating expenses for this year mainly include loss on sale of the property, plant and equipment. For the comparison year, it mainly included costs related to the change of ownership from Biogen Inc. to FUJIFILM Corporation, cost for transition services and support from Biogen Inc. and write off for fixed assets.



# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

DKK'000

	2020/21 12 months	2019/20 15 months		
<b>6 Financial income</b>				
Interest receivable, group entities	0	4,964		
Exchange adjustments	2,393	175		
Exchange gain	24,466	23,075		
Other financial income	644	0		
	27,503	28,214		
<b>7 Financial expenses</b>				
Interest expenses, group entities	6,545	1,128		
Exchange adjustments	0	9,868		
Exchange losses	106,205	5,580		
Other financial expenses	0	666		
	112,750	17,242		
<b>8 Tax for the year</b>				
Estimated tax charge for the year	8,126	4,496		
Deferred tax adjustments in the year	21,075	-54,212		
	29,201	-49,716		
<b>9 Intangible assets</b>				
DKK'000				
	Acquired intangible assets	Knowhow and Customer Rights	Intangible assets in progress	Total
Cost at 1 April 2020	145,707	549,610	90,435	785,752
Additions	0	0	48,502	48,502
Transferred	85,582	0	-85,582	0
Cost at 31 March 2021	231,289	549,610	53,355	834,254
Impairment losses and amortisation at 1 April 2020	53,493	91,602	0	145,095
Amortisation for the year	37,743	137,403	0	175,146
Impairment losses and amortisation at 31 March 2021	91,236	229,005	0	320,241
<b>Carrying amount at 31 March 2021</b>	140,053	320,605	53,355	514,013

# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

#### 10 Property, plant and equipment

DKK'000	Land and buildings	Fixtures and fittings, other plant and equipment	Leasehold improvements	Property, plant and equipment in progress	Total
Cost at 1 April 2020	2,941,092	2,742,894	12,884	56,620	5,753,490
Additions in the year	0	0	0	473,378	473,378
Disposals in the year	0	-15,808	0	0	-15,808
Transferred	2,309	31,835	0	-34,144	0
Cost at 31 March 2021	2,943,401	2,758,921	12,884	495,854	6,211,060
Impairment losses and depreciation at 1 April 2020	1,080,334	1,201,245	12,884	0	2,294,463
Amortisation/depreciation in the year	127,674	184,910	0	0	312,584
Amortisation/depreciation and impairment of disposals in the year	0	-11,310	0	0	-11,310
Impairment losses and depreciation at 31 March 2021	1,208,008	1,374,845	12,884	0	2,595,737
<b>Carrying amount at 31 March 2021</b>	<b>1,735,393</b>	<b>1,384,076</b>	<b>0</b>	<b>495,854</b>	<b>3,615,323</b>

#### 11 Prepayments

Prepayments include accrual of expenses relating to subsequent financial years, including rent and accrued Pharmaceutical Operations & Technology expenses.

	2020/21	2019/20
<b>12 Share capital</b>		
Analysis of the share capital:		
3,850 A shares of DKK 100.00 nominal value each	385	385
50 B shares of DKK 100.00 nominal value each	5	5
	<b>390</b>	<b>390</b>

The Company's share capital has remained DKK 390 thousand over the past 5 years.

# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

DKK'000	2020/21	2019/20
<b>13 Deferred tax</b>		
Deferred tax at 1 April	181,871	236,083
Deferred tax adjustments in the year, recognized in the income statement	21,074	-54,212
<b>Deferred tax at 31 March</b>	202,945	181,871
Deferred tax relates to:		
Intangible assets	17,921	20,352
Property, plant and equipment	235,121	240,385
Tax loss	-50,097	-78,866
	202,945	181,871

The provision for deferred tax primarily relates to timing differences in respect of intangible assets, property, plant and equipment.

### 14 Contractual obligations and contingencies, etc.

#### Other contingent liabilities

The Company is jointly taxed with FUJIFILM Diosynth Biotechnologies Holdings Denmark ApS, which acts as management company, and is jointly and severally liable with other jointly taxed group entities for payment of income taxes for the income year 2013 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 1 July 2012.

#### Other financial obligations

Other rent and lease liabilities:

	2020/21	2019/20
Rent and lease liabilities	20,178	5,638

Rent and lease liabilities concerning contracts which are interminable until 2024 with remaining contract terms of 1-3 years.

### 15 Collateral

The Company has not provided any security or other collateral in assets at 31 March 2021.

# Financial statements

## 1 April 2020 - 31 March 2021

### Notes to the financial statements

#### 16 Related parties

FUJIFILM Diosynth Biotechnologies Denmark ApS' related parties comprise the following:

##### Parties exercising control

Related party	Domicile	Basis for control
Fujifilm Holdings Corporation	9-7-3, AKASAKA, TOKYO MIDTOWN WEST, MINATOKU, TOKYO, Japan 107- 0052	Participating interest
FUJIFILM Diosynth Biotechnologies Holdings Denmark ApS	Biotek Allé 1, 3400, Hillerød Denmark	Participating interest

##### Information about consolidated financial statements

Parent	Domicile	Requisitioning of the parent company's consolidated financial statements
Fujifilm Holdings Corporation	9-7-3, AKASAKA, TOKYO MIDTOWN WEST, MINATOKU, TOKYO, Japan 107- 0052	The consolidated accounts of Fujifilm Holdings Corporation can be obtained by written application to 9-7-3, AKASAKA, TOKYO MIDTOWN WEST, MINATOKU, TOKYO, Japan 107- 0052

##### Related party transactions

FUJIFILM Diosynth Biotechnologies Denmark ApS was engaged in the below related party transactions:

DKK'000	2020/21 12 months	2019/20 15 months
Sales of Service	775	860,593
Purchase of Service	46,782	388,070
Royalty	46,180	0
Purchase of materials	5,296	0
Sales of materials	76	0


#### 17 Fee to the auditors appointed by the Company in general meeting

Statutory audit fee	1,375	1,500
Other services	135	0
	<u>1,510</u>	<u>1,500</u>

#### 18 Appropriation of profit/loss

##### Recommended appropriation of profit/loss

Retained earnings/accumulated loss	103,550	-176,316
	<u>103,550</u>	<u>-176,316</u>





**Denmark**

Biotek Allé 1,  
3400 Hillerød, DK  
Tel: +45 7741 6000  
CVR no. 26 06 07 02

---

**United Kingdom**

Belasis Avenue, Billingham  
TS23 1LH, UK  
Tel: +44 (0) 1642 363511

**USA**

101 J. Morris Commons Lane,  
Morrisville, North Carolina 27560, USA  
Tel: +1 (919) 337 4477

**USA**

3939 Biomedical Way,  
College Station, TX 77845, USA  
Tel: +1 (979) 431 3500

---

[www.fujifilm Diosynth.com](http://www.fujifilm Diosynth.com)